“The FMBA has submitted a dossier to the Russian Ministry of Health to obtain permission for a post-registration clinical trial of a drug for the treatment of a new coronavirus infection MIR 19,” TASS reports.
As noted, the drug is planned to be used "for medical use in an outpatient setting in the first days after the diagnosis of a new coronavirus infection is confirmed."
Earlier, the Federal Medical and Biological Agency submitted an application to the Russian Ministry of Health for registration of the Convasel vaccine against coronavirus infection.